
Cala launched its next-generation kIQ Plus tremor wearable nationwide for essential tremor and Parkinson's disease. The prescription device adds three selectable stimulation waveforms and recalibration before each session. Company-reported data presented at AAN showed 76-89% of patients achieved at least a one-point improvement in TETRAS performance scores across modes. The device is covered by Medicare for eligible patients.